['neoplasms', 'neoplasms, glandular and epithelial', 'neoplasms by histologic type', 'bronchial neoplasms', 'lung neoplasms', 'respiratory tract neoplasms', 'thoracic neoplasms', 'digestive system neoplasms', 'endocrine gland neoplasms', 'carcinoma, non-small-cell lung', 'lung diseases', 'breast diseases', 'renal neoplasm', 'solid tumors']
['entinostat', 'pembrolizumab']

        Inclusion Criteria:

          1. Completed Study SNDX-275-0140 (NCT02897778)

          2. Any AE or toxicity experienced in Study SNDX-275-0140 (NCT02897778) is resolved to
             less than or equal to Grade 1

          3. Continues to meet inclusion criteria for Study SNDX-275-0140 (NCT02897778) at the time
             of entry into this study

        Exclusion Criteria:

          1. Completed Study SNDX-275-0140 (NCT02897778) more than 30 days prior to Cycle 1 Day 1
             of this study

          2. Continues to meet exclusion criteria for Study SNDX-275-0140 (NCT02897778) at the time
             of entry into this study
      